    
Version 1.0 Page 1 of 28                                                         05-May-2025    Cognitive Behavioural Therapy to Optimize Post-Operative Recovery (COPE): A Randomized Controlled Trial    STATISTICAL ANALYSIS PLAN   SAP Version: 1.0  Protocol Version: 3.0  SAP Revisions: None  Date: 05-May-2025  Trial Registration: clinicaltrials.gov, [STUDY_ID_REMOVED]. Registered February 14, 2020, https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]   Reviewed  and Approved  by:    Dr. Jason  W. Busse   
(Principal  Investigator)   Signature:  Date:   
 Dr. Sheila  Sprague  
(Principal  Investigator)  Signature:  
 Date:   
   
	


	



    
Version 1.0 Page 2 of 28                                                         05-May-2025 Document History Date  
(dd-mmm -
yyyy) Drafted/  
Revised By:  Version  
Number  Description of Amendments  05-May-2025  S. Sprague, J. Busse, S. 
Bzovsky, K. Pannozzo, 
N. Fleming  1.0 Initial version              
	


	

    
Version 1.0 Page 3 of 28                                                         05-May-2025 TABLE OF CONTENTS LIST OF FIGURES ...................................................................................................................... 4 List of Tables ................................................................................................................................. 5 LIST OF ABBREVIATIONS ...................................................................................................... 6 1.0 INTRODUCTION................................................................................................................... 7 2.0 TRIAL POPULATION .......................................................................................................... 7 2.1 Patient Flow through the Trial .......................................................................................... 7 2.2 Participant Demographics, Injury, and Fracture Characteristics, and Surgical and Perioperative Care Details ....................................................................................................... 7 2.3 CBT Compliance ................................................................................................................. 8 2.4 Outcome Completion Rates ............................................................................................... 8 3.0 ANALYSIS .............................................................................................................................. 8 3.1 Analysis Methods ................................................................................................................ 8 3.1.1 Primary Analysis ............................................................................................................ 8 3.1.2 Secondary Analyses ....................................................................................................... 9 3.2 Subgroup Analyses............................................................................................................ 10 3.3 Sensitivity and Exploratory Analyses ............................................................................. 11 3.4 Harms ................................................................................................................................. 11 3.5 Statistical Software ........................................................................................................... 11 4.0 FIGURES AND TABLES .................................................................................................... 12 SUPPLEMENTARY TABLES .................................................................................................. 27 REFERENCES ............................................................................................................................ 28   
	


	

    
Version 1.0 Page 4 of 28                                                         05-May-2025 LIST OF FIGURES Figure 1: Consort Flow Chart for Trial Participants ..................................................................... 12  
	


	

    
Version 1.0 Page 5 of 28                                                         05-May-2025 LIST OF TABLES Table 1: Reasons for Exclusion .................................................................................................... 13 Table 2: Reasons for Exclusion after Blinded Central Adjudication Committee Review ............ 14 Table 3: Baseline characteristics ................................................................................................... 15 Table 4: Injury Details and Fracture Characteristics .................................................................... 17 Table 5: CBT Compliance ............................................................................................................ 19 Table 6: CBT Compliance (Condensed to Categories)................................................................. 20 Table 7: Outcome Completion Rates at Follow-up Visits ............................................................ 21 Table 8: Impact of CBT versus Usual Care on Primary and Secondary Outcomes ..................... 22 Table 9: Impact of CBT versus Usual Care on Return to Pre-Injury Function, Work, and Activities ....................................................................................................................................... 23 Table 10: Impact of CBT versus Usual Care on Moderate to Severe PPSP in Different Subgroups....................................................................................................................................................... 24 Table 11: Sensitivity and Exploratory Analyses ........................................................................... 25 Table 12: Treatment-Related Serious Adverse Events and Fracture-Related Complications ...... 26 Table S1: Open Fracture Characteristics ...................................................................................... 27  
	


	

    
Version 1.0 Page 6 of 28                                                         05-May-2025 LIST OF ABBREVIATIONS  aMD  Adjusted mean difference  aOR Adjusted odds ratio  aRR Adjusted risk ratio  BPI-SF Brief Pain Inventory  â€“ Short Form  CBT  Cognitive behavio ural therapy  CI Confidence interval  COPE  Cognitive Behavioural Therapy to Optimize Post -Operative 
Fracture Recovery  HR Hazard ratio  HRQoL  Health -related quality of life  ISS Injury Severity Score  OR Odds ratio  PPSP Persistent  post-surgical pain  SF-36 MSC  Short Form -36 Mental Component Summary  SF-36 PSC Short Form -36 Physical Component Summary  SPOC  Somatic Pre -Occupation and Coping                
	


	

    
Version 1.0 Page 7 of 28                                                         05-May-2025 1.0 INTRODUCTION  The purpose of this statistical analysis plan (SAP) is to outline the primary statistical analyses for the Cognitive Behavioural Therapy to Optimize Post-Operative Recovery (COPE) trial. We will adhere to the CONSORT 2010 guideline when reporting the results of COPE. The structure of this statistical analysis plan follows the Guidelines for the Content of Statistical Analysis Plans in Clinical Trials.1 Additional SAPs will be developed for secondary analyses of trial data.  The primary objective of the COPE trial is to determine if cognitive behavioural therapy (CBT), versus usual care, reduces the prevalence of moderate to severe Persistent Post-Surgical Pain (PPSP) over 12 months post-fracture in participants with an open or closed fracture of the appendicular skeleton.   The secondary objectives of the COPE trial are to determine if CBT, versus usual care: 1) increases physical functioning over 12 months post-fracture, 2) improves mental functioning over 12 months post-fracture, 3) accelerates return to function over 12 months post-fracture, 4) reduces pain severity over 12 months post-fracture, 5) reduces pain interference over 12 months post-fracture, and 6) reduces the proportion of participants using opioid class medications at 6 and 12 months post-fracture in patients with an open or closed fracture of the appendicular skeleton.            2.0 TRIAL POPULATION 2.1 Patient Flow through the Trial The number of patients screened, included, and excluded will be presented in a flow diagram (Figure 1). The figure will include the number of participants who were randomly assigned to the two treatment groups. It will also include the number of participants who were subsequently deemed ineligible by the Central Adjudication Committee.    We will summarize the number of patients excluded by reason (Table 1) and the number of participants deemed ineligible by the Central Adjudication Committee by reason (Table 2).   Participants deemed ineligible by the Central Adjudication Committee will not be included in any analysis, as per guidance from Fergusson et al.2   Figure 1 will include participant follow-up and the number of participants who were lost to follow-up, along with the reason, over the course of the trial.    2.2 Participant Demographics, Injury, and Fracture Characteristics, and Surgical and Perioperative Care Details We will use descriptive measures to summarize participant demographics, baseline information, injury, fracture characteristics, surgical, and perioperative care details of the sample stratified by treatment group (Tables 3 and 4). We will use means and standard deviations (SDs) or medians and interquartile ranges (IQR) for continuous data, and categorical data will be presented as frequencies and percentages. We will examine key baseline differences between those who stopped the CBT program early and those who did not.  We will not statistically test for differences in these characteristics between treatment groups (Section 3.2). The potential clinical importance of any imbalance between treatment groups will be noted.   
	


	

    
Version 1.0 Page 8 of 28                                                         05-May-2025 2.3 CBT Compliance We will report the number of participants randomized to the CBT intervention who completed the CBT modules according to the number of modules completed (0 to 7 modules). We will also look at levels of compliance by key baseline factors including the subgroup analysis factors, participant age (<60 versus â‰¥60), and injury severity (defined as an Injury Severity Score [ISS] greater than or equal to 9).  The data will be presented as frequencies and percentages (Tables 5 and 6).  2.4 Outcome Completion Rates We will report on the outcome completion rates at each follow-up visit. The data will be presented as frequencies and percentages (Table 7).    3.0 ANALYSIS 3.1 Analysis Methods The primary and secondary analyses will be conducted following intention-to-treat (ITT) principles, ensuring that participants are analyzed in their originally assigned treatment groups, regardless of adherence or protocol deviations. The date on which the participantâ€™s fracture(s) occurred will be used as the starting point for all time-to-event analyses.   We will use multiple imputations to account for missing data in the analyses and minimize potential bias under the assumption that the data are missing at random (MAR). This approach will allow for the uncertainty associated with missing values to be properly accounted for, improving the robustness of statistical inferences.3 Additionally, as we anticipate high rates of early withdrawal, we will account for this in the analyses, if needed.  3.1.1 Primary Analysis We will use a mixed effects log-binomial model to determine the association between CBT treatment and moderate to severe PPSP (score of â‰¥4/10) over 12 months post-fracture.  The choice of using a PPSP score of â‰¥4/10 for the primary analysis was based on scores of less than 4 being defined as â€˜mildâ€™ pain, and so less important to patients. Prevalence of moderate to severe PPSP will be our dependent variable. Only the highest PPSP score at each visit will be included for participants with multiple fractures. CBT treatment status, stratification variables (clinical site, sex, at least one open fracture versus no open fracture(s), military, veteran or first responder versus others, and greater illness beliefs [defined as Somatic Pre-Occupation and Coping [SPOC] score â‰¥48] versus lesser illness beliefs [SPOC score <48]), and time of assessment (continuous measure in days) will be included in the model as fixed effects, with patients entered as a random intercept. A time-by-treatment interaction term will also be added to the model, allowing the treatment effect to vary over time. If the interaction between treatment and time is significant (p<0.05), indicating the effect of treatment varying over time, we will report the average treatment effect across 12 months and the treatment effect for each time point of variation. If the interaction between treatment and time is not significant (pâ‰¥0.05), suggesting a constant treatment effect over the study period, we will report the average treatment effect. Results will be reported using marginal standardization as adjusted risk ratios (aRRs) with a 95% confidence interval (95% CI) and p-value (Table 8).  
	


	

    
Version 1.0 Page 9 of 28                                                         05-May-2025 3.1.2 Secondary Analyses  1) Health-Related Quality of Life (HRQoL): We will use linear repeated measures mixed modeling to explore the association between: 1) CBT treatment status and Short Form-36 (SF-36) Physical Component Summary (PCS) scores over 12 months, and 2) CBT treatment status and SF-36 Mental Component Summary (MCS) scores over 12 months. The SF-36 is an established, reliable and validated health status measure.4â€“6 It measures HRQoL through an 8-domain profile of functional health and well-being, physical and mental health summary measures (PCS and MCS).  The SF-36 PCS and MCS are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible. SF-36 PCS and MCS scores will be included as the dependent variable in each corresponding model. CBT treatment status, stratification variables, and time of assessment (continuous measure in days) will be included in the models as fixed effects, with patients entered as a random intercept. The models will also be adjusted for baseline SF-36 PCS and MCS scores, accordingly, as well as including a time-by-treatment interaction term. If the interaction between treatment and time is significant (p<0.05), indicating the effect of treatment varying over time, we will report the average treatment effect across 12 months and the treatment effect for each time point of variation. If the interaction between treatment and time is not significant (pâ‰¥0.05), suggesting a constant treatment effect over the study period, we will report the average treatment effect. Results will be reported using marginal standardization as adjusted mean differences (aMDs) with 95% CIs and p-values (Table 8).   2) Return to Function: We will use Cox proportional hazards regression modeling to explore the association between: 1) CBT treatment status and returning to â‰¥80% of pre-injury functioning, 2) CBT treatment status and returning to full function with respect to work, 3) CBT treatment status and returning to full function with respect to leisure activities, and 4) CBT treatment status and returning to full function with respect to responsibilities around the home. These return to function components are measured using the Return to Function questionnaire, which has been used in a previous fracture trial7 documents when participants return to work, household activities, and leisure activities without limitations, as well as when they achieve 80% of their pre-injury function. Participants will be censored at their last documented follow-up visit. The analyses will adjust for stratification variables and the results will be reported as hazard ratios (HRs) with 95% CIs and p-values (Table 9).  3) Pain over Time: We will use cumulative logit modeling to explore the association of 1) CBT treatment status and Brief Pain Inventory - Short Form (BPI-SF) Average Pain Severity scores over 12 months and 2) CBT treatment status and BPI-SF Pain Interference scores over 12 months. The BPI-SF assesses the severity of pain and its impact on function.8 All items are rated on a 0-10 scale, with higher scores indicating greater pain severity and interference. BPI-SF Average Pain Severity and BPI-SF Pain Interference scores will be included as the dependent variable in each corresponding model. CBT treatment status, stratification variables, and time of assessment (continuous measure in days) will be included in the models as fixed effects, with patients entered as a random intercept. The models will also be adjusted for baseline BPI-SF Average Pain Severity and BPI-SF Pain Interference scores, accordingly, as well as include a time-by-treatment 
	


	

    
Version 1.0 Page 10 of 28                                                         05-May-2025 interaction term. If the interaction between treatment and time is significant (p<0.05), indicating the effect of treatment varying over time, we will report the average treatment effect across 12 months and the treatment effect for each time point of variation. If the interaction between treatment and time is not significant (pâ‰¥0.05), suggesting a constant treatment effect over the study period, we will report the average treatment effect. Results will be reported using marginal standardization as adjusted odds ratios (aORs) with 95% CIs and p-values (Table 8).  4) Opioid Use: We will use logistic regression modeling to explore the association between CBT treatment status and opioid use status. Two separate models will be created to analyze opioid use status (yes versus no) at both 6 months and 12 months. Opioid use status will be included as the dependent variable and each model will be adjusted for stratification variables. Results will be reported as ORs with 95% CIs and p-values (Table 8).   3.2 Subgroup Analyses To explore for treatment effect heterogeneity on trial outcomes, we will use the same analytical approach as specified for the primary outcome above but include a treatment by subgroup interaction term in the model. If we have enough participants to conduct reliable subgroup analyses, we will report results by the prespecified subgroups, which consist of: (1) sex (indicated as male or female), (2) the presence or absence of an eligible open fracture, (3) veteran/military/first responder status (as self-reported by the participant), and (4) SPOC Scores (defined as â‰¥48 or <48).  Towards the end of the trial, prior to unblinding, site location (Canada or the United States) was added as a subgroup in the analyses to assess its potential role as an effect modifier. Results will be reported using marginal standardization and stratified by the subgroup as aORs with 95% CIs, and the interaction p-values in a forest plot and table (Table 10). These analyses will be approached and reported in accordance with best practices and guidelines for subgroup analyses.9â€“13 For subgroup effects that show a statistically significant test of interaction (pâ‰¤0.05), we will use ICEMAN criteria to guide inferences about the credibility of our subgroup analyses.13   Subgroup Analyses Overview Objective  Hypothesis  Subgroup Analysis 1  Males versus females  CBT will be associated with a larger reduction in the prevalence 
of PPSP  in females compared to males . Subgroup Analysis 2  Any open fracture versus no 
open fracture  CBT will be associated with a larger reduction in the prevalence 
of PPSP  in participants with open fractures compared to 
participants with only closed fractures.  Subgroup Analysis 3  Military, veteran, and first 
responders versus other patients  CBT will be associated with a larger reduction in the prevalence 
of PPSP in participants who are employed by the military, 
veterans, or first responders.  Subgroup Analysis 4  
	


	

    
Version 1.0 Page 11 of 28                                                         05-May-2025 Objective  Hypothesis  Higher versus lower SPOC 
scores  CBT will be associated with a larger reduction in the prevalence 
of PPSP  in participants with higher versus  lower SPOC scores.  Subgroup Analysis 5  Site location (Canada versus  the 
United States)  CBT will be associated with a larger reduction in the preva lence 
of PPSP in participants from sites located in Canada.   3.3 Sensitivity and Exploratory Analyses We will conduct the following additional analyses to explore the robustness of our findings:  1. Assess if CBT, versus usual care, reduces the prevalence of any severity of PPSP over 12-months post-fracture (Table 11).  2. A sensitivity analysis limited to the primary outcome to compare those participants randomized to the CBT intervention at the primary site, defined as the site with the highest CBT compliance (Table 11)    3. Assess the primary outcome in only those participants randomized to the CBT intervention who fully adhered to: 1) at least three CBT modules and 2) at least six CBT modules (Table 11), limiting data to the primary site only, defined as the highest enrolling site.   These analyses will help determine whether greater engagement with CBT is associated with improved outcomes. The exploratory and sensitivity analyses will follow the same analysis methods as described for the primary outcome, including appropriate regression models and adjustments for stratification variables.  3.4 Harms The number and percentage of patients experiencing treatment-related serious adverse events and fracture-related complications will be presented by treatment arm (Table 12). No formal statistical testing will be undertaken.  3.5 Statistical Software All analyses will be performed using R (version 4.4.3 or newer, R Foundation for Statistical Computing, Vienna, Austria).  
	


	

    
Version 1.0 Page 12 of 28                                                         05-May-2025 4.0 FIGURES AND TABLES   Figure 1: Consort Flow Chart for Trial Participants                                *Please refer to Table 1 for reasons for exclusion **Please refer to Table 2 for reasons for ineligibility per the Central Adjudication CommitteeExcluded (n= XX)* 
 Randomized  (n=XX ) Cognitive Behavioural Therapy (n= XX) 
Participants with primary 
outcome completed at 12 -
month follow -up 
(n =XX) 
 
   Died (n= XX) 
   Unable to locate (n= XX) 
   Withdrew consent (n= XX) Ineligible per Central 
Adjudication Committee  
(n = XX)**  
 
Withdrew consent 
immediately after 
randomization (n =XX)  
 
 
 
 
 
 
ee (n=XX)** 
 Fracture p atients ï‚³18 years treated with internal 
fixation  (n=XX) 
 
Ineligible per Central 
Adjudication 
Committee  (n=XX)** 
 
Withdrew consent 
immediately after 
randomization (n =XX)  
 Participants with primary 
outcome completed at 12 -
month follow -up 
(n =XX) 
 
   Died (n=XX)  
   Unable to locate (n=XX)  
   Withdrew consent (n=XX)  Usual Care  
(n=XX) 
Participants included in 
primary analysis  (n=XX)  Participants included in 
primary analysis  (n=XX)  
 
	


	

    
Version 1.0 Page 13 of 28                                                         05-May-2025 Table 1: Reasons for Exclusion Reasons for Exclusion  Total  
(n= XX  patients 
excluded ) Patient does not have an eligible fracture , n (%)  Patient has a concomitant injury which, in the opinion of the attending 
surgeon, is likely to impair function for as long as or longer than the 
patientâ€™s extremity fracture(s), n (%)   Patient is facing current or impending incarceration   Currently not experiencing any pain in the fracture region despite being 
fully weight bearing, n (%)   Patient has active psychosis, n (%)   Patient has active suicidality, n (%)   Patient has an active substance use disorder that, in the judgement of the 
treating surgeon, would interfere in the patientâ€™s ability to partake in the 
CBT and/or the study , n (%)   Patient does not have the cognitive ability and language skills to 
participate in CBT , n (%)   Patient is already participating in or planning to start other psychological 
treatments (including CBT) within the duration of the study (12 months) , 
n (%)   Patient does not have consistent online access from a smartphone/internet -
enabled device with a minimum operating system able to use the CBT 
provider's application , n (%)   Anticipated problems, in the judgement of study personnel, with the 
patient participating in CBT intervention and/or returning for follow -up, n 
(%)  Patient is not willing to participate in CBT , n (%)   Currently enrolled in a study that does not permit co -enrolment in other 
trials , n (%)   Previously enrolled in the COPE trial , n (%)   Patient was not screened /approached within 2 -12 weeks following their 
fracture, n (%)   Patientâ€™s fracture was not treated operatively with internal f ixation, n (%)   Patient did not provide informed consent, n (%)   
	


	

    
Version 1.0 Page 14 of 28                                                         05-May-2025 Table 2: Reasons for Exclusion after Blinded Central Adjudication Committee Review   
Reasons for Exclusion  Number of Patients Excluded 
Following Adjudication  CBT  
(n= XX  adjudicated 
as ineligible ) Usual Care  
(n= XX  
adjudicated as 
ineligible ) Fragility fracture (a fall from a standing height or less, that 
results in a fracture) as their only extremity fracture treated 
with internal fixation, n (%)    Stress fracture as their only extremity fracture treated with 
internal fixation, n (%)    Patient  has a concomitant  injury  which,  in the opinion  of 
the attending  surgeon,  is likely  to impair  function  for as 
long as or longer  than the patientâ€™s extremity  fracture(s) , n 
(%)   Patient is facing current or impending incarceration    Currently not experiencing any pain in the fracture region 
despite being fully weight bearing, n (%)    Patient has active psychosis, n (%)    Patient has active suicidality, n (%)    Patient has an active substance use disorder that, in the 
judgement of the treating surgeon, would interfere in the 
patientâ€™s ability to partake in the CBT and/or the study , n 
(%)   Patient does not have the cognitive ability and language 
skills to participate in CBT , n (%)    Patient is already participating in or planning to start other 
psychological treatments (including CBT) within the 
duration of the study (12 months) , n (%)    Patient does not have consistent online access fr om a 
smartphone/internet -enabled device with a minimum 
operating system able to use the CBT provider's 
application , n (%)    Anticipated problems, in the judgement of study personnel, 
with the patient participating in CBT intervention and/or 
returning for follow -up, n (%)    Patient is not willing to participate in CBT , n (%)    Currently enrolled in a study that does not permit co -
enrolment in other trials , n (%)    Previously enrolled in the COPE trial , n (%)    Patient was not screened/approached within 2-12 weeks 
following their fracture , n (%)    Patientâ€™s fracture was not treated operatively with internal 
fixation , n (%)    Patient did not provide informed consent , n (%)    Patient is under 18 years of age , n (%)    Another reason to exclude the patient (must be approved 
by the Methods Centre) , n (%)    
	


	

    
Version 1.0 Page 15 of 28                                                         05-May-2025 Table 3: Baseline characteristics   CBT  
(n= XX) Usual Care  
(n= XX) Age in years, mean (SD)    Sex, n (%)â€¯   
â€¯â€¯â€¯â€¯ Femaleâ€¯   
â€¯â€¯â€¯â€¯ Maleâ€¯  
â€¯â€¯â€¯â€¯ Did not want to disclose    Body mass index  in kg/m2, n (%)â€¯  
â€¯â€¯â€¯â€¯ Underweight (BMI < 18.5)â€¯   
â€¯â€¯â€¯â€¯ Normal weight (18.5 â€“ 24.9)â€¯  
â€¯â€¯â€¯â€¯ Overweight (25 â€“ 29.9)â€¯  
â€¯â€¯â€¯â€¯ Obese (BMI  â‰¥ 30)â€¯  
    Did not want to disclose    Race or ethnicity, n (%)  
â€¯â€¯â€¯â€¯ White  
â€¯â€¯â€¯â€¯ South Asian  
    East Asian  
    Southeast Asian  
    Middle Eastern  
    People of African and/or Caribbean Descent  
    Indigenous  
    Latinx  
    Multiethnic Background   
    Did not want to disclose    Latin or Hispanic origin, n (%)    Employment prior to injury, n (%)    First responder, n (%)  
â€¯â€¯â€¯â€¯ Police officer  
â€¯â€¯â€¯â€¯ Firefighter  
    Emergency medical technician  
    Paramedic  
    Search and rescue personnel    Military employment histor y, n (%)  
â€¯â€¯â€¯â€¯ Active duty   
    Reserve/Guard   
    Veteran/Retiree  
    Civilian    Highest level of education completed, n (%)  
â€¯â€¯â€¯â€¯ 8th grade or less  
    9th to 12th grade, no diploma  
    General education diploma or high school graduate  
    Some college, no degree  
    Associates degree (2 -year degree)  
    Bachelors/college degree  
    Some graduate work, no degree  
    Graduate degree  
    Professional degree  
    Did not want to disclose    
Current smoker, n (%)    
	


	

    
Version 1.0 Page 16 of 28                                                         05-May-2025   CBT  
(n= XX) Usual Care  
(n= XX) Functional Comorbidity Index, mean (SD)â€¯    Receiving other mental health support, n (%) * 
â€¯â€¯â€¯â€¯ Counselling  
â€¯â€¯â€¯â€¯ Support group  
    Other    Receiving medication for mental health support, n (%)*  
       Antidepressant medications  
       Antipsychotic medications  
       Mood stabilizers  
       Psychostimulants, stimulants  
       Anxiolytics  
       Central nervous system depressants  
       Substance abuse medications  
       Cognitive enhancers  
       Other    
Taking pain medication in the past two weeks, n (%)*          
    Acetaminophen (e.g., Tylenol)  
    Opioids (e.g., oxycodone, Dilaudid)  
    NSAIDs (e.g., ibuprofen, Al eve, naproxen)  
    GABA Analogue (e.g., Neurontin, Lyrica)  
    Benzodiazepines (e.g., diazepam)  
    Cannabis  
    Other    Baseline SPOC Score ** 
   Low (<48)  
   Moderate/high (â‰¥48)    *Some participants specified more than one type of mental health support/medication. **SPOC: Somatic Pre-Occupation and Coping  
	


	

    
Version 1.0 Page 17 of 28                                                         05-May-2025 Table 4: Injury Details and Fracture Characteristics   CBT  
(n= XX)  Usual Care  
(n= XX)  Mechanism of injury, n (%)  
â€¯â€¯â€¯â€¯ Motor vehicle accident  
â€¯â€¯â€¯â€¯ Fall 
â€¯â€¯â€¯â€¯ Direct trauma (penetrating)  
â€¯â€¯â€¯â€¯ Direct trauma (blunt)  
â€¯â€¯â€¯â€¯ Crush injury  
â€¯â€¯â€¯â€¯ Twist injury  
â€¯â€¯â€¯â€¯ Blast injury  
â€¯â€¯â€¯â€¯ Ballistic injury  
â€¯â€¯â€¯â€¯ Spontaneous    
Work -related injury, n (%)    Injury severity score, mean ( SD)   American Society of Anesthesiologists (ASA) physical 
class, n (%)  
â€¯â€¯â€¯â€¯ Class I  or II 
â€¯â€¯â€¯â€¯Class III  or higher    Days from injury to admission, mean (SD)    Duration of hospital stay (days), mean (SD)    Fractur e type, n (%)  
â€¯â€¯â€¯â€¯Open 
â€¯â€¯â€¯â€¯Closed 
â€¯â€¯â€¯â€¯Both   Number of included fractures per patient, n (%)  
â€¯â€¯â€¯â€¯1 
â€¯â€¯â€¯â€¯2 
â€¯â€¯â€¯â€¯3 
â€¯â€¯â€¯â€¯4 
â€¯â€¯â€¯â€¯5 or more    Location of fracture, n (%)  
â€¯â€¯â€¯â€¯Upper extremity  
â€¯â€¯â€¯â€¯Lower extremity  
â€¯â€¯â€¯â€¯Both   AO/OTA  classification, n (%)  
â€¯â€¯â€¯â€¯11 A -C 
â€¯â€¯â€¯â€¯12 A -C 
â€¯â€¯â€¯â€¯13 A -C 
â€¯â€¯â€¯â€¯14 A -C 
â€¯â€¯â€¯â€¯15 A -C 
â€¯â€¯â€¯â€¯2R1 A -C 
â€¯â€¯â€¯â€¯2R2 A -C 
â€¯â€¯â€¯â€¯2R3 A -C 
â€¯â€¯â€¯â€¯2U1 A -C 
â€¯â€¯â€¯â€¯2U2 A -C 
â€¯â€¯â€¯â€¯2U3 A -C 
â€¯â€¯â€¯â€¯31 A -C N=XX fractures  N=XX fractures  
	


	

    
Version 1.0 Page 18 of 28                                                         05-May-2025 â€¯â€¯â€¯â€¯32 A -C 
â€¯â€¯â€¯â€¯33 A -C 
â€¯â€¯â€¯â€¯34 A -C 
â€¯â€¯â€¯â€¯41 A -C 
â€¯â€¯â€¯â€¯42 A -C 
â€¯â€¯â€¯â€¯43 A -C 
â€¯â€¯â€¯â€¯4F1 A -C 
â€¯â€¯â€¯â€¯4F2 A -C 
â€¯â€¯â€¯â€¯4F3 A -C 
â€¯â€¯â€¯â€¯44 A -C 
â€¯â€¯â€¯â€¯61 A -C 
â€¯â€¯â€¯â€¯62 A -C 
â€¯â€¯â€¯â€¯71 A -C 
â€¯â€¯â€¯â€¯72 A -C 
â€¯â€¯â€¯â€¯73 A -C 
â€¯â€¯â€¯â€¯74 A -C 
â€¯â€¯â€¯â€¯75 A -C 
â€¯â€¯â€¯â€¯76 A -C 
â€¯â€¯â€¯â€¯77 A -C 
â€¯â€¯â€¯â€¯78 A -C 
â€¯â€¯â€¯â€¯79 A -C 
â€¯â€¯â€¯â€¯81 A -C 
â€¯â€¯â€¯â€¯82 A -C 
â€¯â€¯â€¯â€¯83 A -C 
â€¯â€¯â€¯â€¯84 A -C 
â€¯â€¯â€¯â€¯85 A -C 
â€¯â€¯â€¯â€¯86 A -C 
â€¯â€¯â€¯â€¯87 A -C 
â€¯â€¯â€¯â€¯88 A -C 
â€¯â€¯â€¯â€¯89 A -C Severe soft tissue injury  for closed fractures , n (%)  
â€¯â€¯â€¯â€¯Extensive skin contusion or crush injury  
â€¯â€¯â€¯â€¯Severe damage to underlying muscle  
â€¯â€¯â€¯â€¯Compartment syndrome  
â€¯â€¯â€¯â€¯Degloving  N=XX closed 
fractures  N=XX closed 
fractures  Type of internal fixation, n (%)  
â€¯â€¯â€¯â€¯Intramedullary nail  
â€¯â€¯â€¯â€¯Plate(s) and adjacent screws  
â€¯â€¯â€¯â€¯Screw(s) alone  
â€¯â€¯â€¯â€¯K-wire(s)  
â€¯â€¯â€¯â€¯Cerclage  
â€¯â€¯â€¯â€¯Other  N=XX fractures  N=XX fractures  
	


	

    
Version 1.0 Page 19 of 28                                                         05-May-2025 Table 5: CBT Compliance (n=XX)   Number of CBT Modules Completed   None  1 2 3 4 5 6 7 All Participants 
Randomized to CBT          Sex    Male , n (%)              Female , n (%)          Fracture Type      Any o pen fracture , n (%)             No open  fracture , n (%)          Background/Employment      Military, veteran, and first  
   responder , n (%)             Not a veteran, first  
   responder or employed by  
   the military , n (%)          SPOC Score      Low (<48) , n (%)             Moderate/high (â‰¥48) , n  
    (%)         Site Location      Canada , n (%)             United States , n (%)          Age             <60, n (%)             â‰¥60, n (%)          Injury Severity Score             <9, n (%)             â‰¥9, n (%)            
	


	

    
Version 1.0 Page 20 of 28                                                         05-May-2025 Table 6: CBT Compliance (Condensed to Categories) (n=XX)  Number of CBT Modules Completed   None  1-3 4-6 7 All Participants Randomized to CBT,  n (%)       Sex        Male , n (%)          Female , n (%)      Fracture Type          Any o pen fracture , n (%)         No open  fracture , n (%)      Background/Employment          Military, veteran, and first responder , n (%)         Not a veteran, first responder or employed by  
   the military , n (%)      SPOC Score          Low (<48) , n (%)         Moderate/high (â‰¥48) , n (%)      Site Location          Canada , n (%)         United States , n (%)      Age         <60, n (%)         â‰¥60, n (%)      Injury Severity Score         <9, n (%)         â‰¥9, n (%)        
	


	

    
Version 1.0 Page 21 of 28                                                         05-May-2025 Table 7: Outcome Completion Rates at Follow-up Visits (N=XX total sample size)  Outcome  3 months  6 months  9 months  12 months  PPSP Form , n (%)       SF-36 Form, n (%)      Return to Function Form, n (%)      BPI-SF Form,  n (%)       Opioid Class Medication  
Question , n (%)      
	


	

    
Version 1.0 Page 22 of 28                                                         05-May-2025 Table 8: Impact of CBT versus Usual Care on Primary and Secondary Outcomes Outcome  CBT  
(n= XX)  Usual Care  
(n= XX)  Estimate**   
 (95% CI)    p-value   Primary Outcome  Moderate to Severe (â‰¥4/10)  PPSP , n 
(%)      Secondary Outcomes  SF-36 PCS , mean (SD)      SF-36 MCS , mean (SD)      BPI-SF Average Pain Severity 
Score , mean (SD)      BPI-SF Pain Interference Score , 
mean (SD)      Taking an opioid class medication, n 
(%)     **Estimates are presented as an adjusted risk ratio for the primary outcome, as adjusted odds ratios for the BPI-SF outcomes, as an odds ratio for the opioid use outcome, and as adjusted mean differences for the remainder of the secondary outcomes.     
	


	

    
Version 1.0 Page 23 of 28                                                         05-May-2025 Table 9: Impact of CBT versus Usual Care on Return to Pre-Injury Function, Work, and Activities Function Category   Hazard Ratio  
(95% CI)  p-value   â‰¥80% of Pre-injury Functioning , n (%)  
   CBT vs. No CBT    Work*, n (%)  
   CBT  vs. No CBT       Leisure Activities, n (%)  
   CBT vs. No CBT      Responsibilities around the Home, n (%)  
   CBT vs. No CBT      *Unemployed participants were excluded from analyses 
	


	

    
Version 1.0 Page 24 of 28                                                         05-May-2025 Table 10: Impact of CBT versus Usual Care on Moderate to Severe PPSP in Different Subgroups Subgroup  CBT  
(n= XX)  Usual Care  
(n= XX)  Adjusted Risk  Ratio   
 (95% CI)    Interaction 
p-value   Sex    Male         Female      Fracture Type     Any o pen fracture , n (%)         No open fracture , n (%)      Background/Employment     Military, veteran, and first  
   responder         Not a veteran, first responder  
   or employed by the military      SPOC Score     Low (<48)         Moderate/high (â‰¥48)      Site Location     Canada         United States      
	


	

    
Version 1.0 Page 25 of 28                                                         05-May-2025 Table 11: Sensitivity and Exploratory Analyses Outcome  CBT  
(n= XX)  Usual Care  
(n= XX)  Adjusted Risk Ratio   
 (95% CI)    p-value   Exploratory Outcome â€“ Any Severity of PPSP  PPSP Severity, n (%)  
     Any severity  (â‰¥1/10)  
  
  
  
 Primary Outcome - Participants randomized to the CBT intervention at the primary site  PPSP Severity, n (%)   
     Moderate to Severe (â‰¥4/10)      Primary Outcome  â€“ Adherence to at least three CBT modules  at the primary site  PPSP Severity, n (%)   
     Moderate to Severe (â‰¥4/10)      Primary Outcome â€“ Adherence to at least six CBT modules  at the primary site  PPSP Severity, n (%)   
     Moderate to Severe (â‰¥4/10 )     
	


	

    
Version 1.0 Page 26 of 28                                                         05-May-2025 Table 12: Treatment-Related Serious Adverse Events and Fracture-Related Complications Category  CBT  
(n= XX)  Usual Care  
(n= XX)  Serious adverse event, n (%)    Fracture -related complication, n (%)         Wound healing problem         Compartment syndrome         Superficial infection         Deep/Organ/Space infection         Delayed union         Nonunion         Malunion         Implant failure/breakage         Dislocation/instability         Heterotopic ossification         Osteolysis         Avascular necrosis         Pain (not otherwise covered)         Other    
	


	

    
Version 1.0 Page 27 of 28                                                         05-May-2025 SUPPLEMENTARY TABLES  Table S1: Open Fracture Characteristics   CBT  
(n= XX  open 
fractures ) Usual Care  
(n= XX  open 
fractures ) Gustilo classification, n (%)  
â€¯â€¯â€¯â€¯I 
â€¯â€¯â€¯â€¯II 
â€¯â€¯â€¯â€¯IIIA 
â€¯â€¯â€¯â€¯IIIB 
â€¯â€¯â€¯â€¯IIIC   Skin, n (%)  
â€¯â€¯â€¯â€¯Laceration with edges that approximate  
â€¯â€¯â€¯â€¯Laceration with edges that do not approximate  
â€¯â€¯â€¯â€¯Laceration associated with extensive degloving    Muscle, n (%)  
â€¯â€¯â€¯â€¯ No appreciable muscle necrosis, some muscle injury  
â€¯â€¯â€¯â€¯ with intact muscle function  
â€¯â€¯â€¯â€¯ Loss of muscle but the muscle remains functional,  
â€¯â€¯â€¯â€¯ some localized necrosis in the zone of injury that  
â€¯â€¯â€¯â€¯ requires excision, intact muscle -tendon unit  
â€¯â€¯â€¯â€¯ Dead muscle, loss of muscle function, partial or  
â€¯â€¯â€¯â€¯ complete compartment excision, complete  
â€¯â€¯â€¯â€¯ disruption of a muscle -tendon unit, muscle defect  
â€¯â€¯â€¯â€¯ does not reapproximate    
Arterial, n (%)  
â€¯â€¯â€¯â€¯No major vessel disruption  
â€¯â€¯â€¯â€¯Vessel injury without distal ischemia  
â€¯â€¯â€¯â€¯Vessel injury with distal ischemia    Contamination, n (%)  
â€¯â€¯â€¯â€¯None or minimal contamination  
â€¯â€¯â€¯â€¯Surface contamination (not ground in)  
â€¯â€¯â€¯â€¯Contaminant embedded in bone or deep soft tissues  
â€¯â€¯â€¯â€¯or high risk environmental conditions (barnyard,  
â€¯â€¯â€¯â€¯fecal, dirty water, etc.)    Bone, n (%)  
â€¯â€¯â€¯â€¯None 
â€¯â€¯â€¯â€¯Bone missing or devascularized bone fragments, but  
â€¯â€¯â€¯â€¯still some contact between proximal and distal  
â€¯â€¯â€¯â€¯fragments  
â€¯â€¯â€¯â€¯Segmental bone loss â€¯â€¯â€¯â€¯    
	


	

    
Version 1.0 Page 28 of 28                                                         05-May-2025 REFERENCES 1. Gamble C, Krishan A, Stocken D, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337-2343. 2. Fergusson D, Aaron SD, Guyatt G, HÃ©bert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325(7365):652-654. 3. Zhang Y, Alyass A, Vanniyasingam T, et al. A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. J Clin Epidemiol. 2017;88:67-80. 4. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey of Scales and Preliminary Construction Tests of Reliability and Validity. Med Care. 1996;34(3):220-233. doi:10.2307/3766749 5. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001;45(4):384-391. 6. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):46-50. 7. Busse JW, Bhandari M, Einhorn TA, et al. Re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST): randomized clinical trial. BMJ. 2016;355:i5351. 8. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133-137. 9. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194. 10. Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: usersâ€™ guide to the medical literature. JAMA. 2014;311(4):405-411. 11. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117. 12. Sun X, Briel M, Busse JW, et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials. 2009;10:101. 13. Schandelmaier S, Briel M, Varadhan R, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Can Med Assoc J. 2020;192(32):E901-E906. doi:10.1503/cmaj.200077  
	


	
